Clinical trial
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
NCT03383094
Study timeline
Study start (actual)2018-03-15Date precision: day
Registry last updated2025-10-07
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Head and Neck Squamous Cell Carcinomaunresolved
Cancerunresolved
Cancer of Head and Neckunresolved
Cancer, Advancedunresolved
Cancer, Metastaticunresolved
Tumorunresolved
Tumor Recurrenceunresolved
Tumor Neckunresolved
Tumor Metastasisunresolved
Oral Cancerunresolved
Oropharyngeal Cancerunresolved
Oropharynx Cancerunresolved
Oropharynx Cancer, Stage IIIunresolved
Oropharynx Cancer, Recurrentunresolved
Oropharynx Cancer, Metastaticunresolved
Interventions
PembrolizumabDRUG · verified · RxNorm: pembrolizumab
Radiation therapyRADIATION
CisplatinDRUG · verified · RxNorm: cisplatin
Sponsors & collaborators
Loren Mell, MDlead sponsor
Merck Sharp & Dohme LLCcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03383094 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.